|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CDCA8 |
Gene summary for CDCA8 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CDCA8 | Gene ID | 55143 |
| Gene name | cell division cycle associated 8 | |
| Gene Alias | BOR | |
| Cytomap | 1p34.3 | |
| Gene Type | protein-coding | GO ID | GO:0000070 | UniProtAcc | Q53HL2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55143 | CDCA8 | LZE2T | Human | Esophagus | ESCC | 2.18e-04 | 8.12e-01 | 0.082 |
| 55143 | CDCA8 | LZE6T | Human | Esophagus | ESCC | 2.96e-03 | 2.14e-01 | 0.0845 |
| 55143 | CDCA8 | P2T-E | Human | Esophagus | ESCC | 4.40e-09 | 5.17e-01 | 0.1177 |
| 55143 | CDCA8 | P4T-E | Human | Esophagus | ESCC | 3.78e-04 | 1.58e-01 | 0.1323 |
| 55143 | CDCA8 | P5T-E | Human | Esophagus | ESCC | 1.62e-13 | 3.70e-01 | 0.1327 |
| 55143 | CDCA8 | P9T-E | Human | Esophagus | ESCC | 4.01e-04 | 1.43e-01 | 0.1131 |
| 55143 | CDCA8 | P10T-E | Human | Esophagus | ESCC | 4.41e-07 | 2.59e-01 | 0.116 |
| 55143 | CDCA8 | P15T-E | Human | Esophagus | ESCC | 1.35e-04 | 1.64e-01 | 0.1149 |
| 55143 | CDCA8 | P16T-E | Human | Esophagus | ESCC | 8.40e-04 | 1.05e-01 | 0.1153 |
| 55143 | CDCA8 | P17T-E | Human | Esophagus | ESCC | 3.52e-10 | 4.64e-01 | 0.1278 |
| 55143 | CDCA8 | P19T-E | Human | Esophagus | ESCC | 5.57e-05 | 6.18e-01 | 0.1662 |
| 55143 | CDCA8 | P20T-E | Human | Esophagus | ESCC | 2.32e-06 | 3.41e-01 | 0.1124 |
| 55143 | CDCA8 | P21T-E | Human | Esophagus | ESCC | 9.35e-10 | 4.18e-01 | 0.1617 |
| 55143 | CDCA8 | P23T-E | Human | Esophagus | ESCC | 3.36e-03 | 1.80e-01 | 0.108 |
| 55143 | CDCA8 | P24T-E | Human | Esophagus | ESCC | 1.88e-11 | 3.58e-01 | 0.1287 |
| 55143 | CDCA8 | P27T-E | Human | Esophagus | ESCC | 1.66e-02 | 1.17e-01 | 0.1055 |
| 55143 | CDCA8 | P28T-E | Human | Esophagus | ESCC | 2.06e-08 | 1.77e-01 | 0.1149 |
| 55143 | CDCA8 | P31T-E | Human | Esophagus | ESCC | 9.53e-09 | 2.92e-01 | 0.1251 |
| 55143 | CDCA8 | P32T-E | Human | Esophagus | ESCC | 4.12e-11 | 2.70e-01 | 0.1666 |
| 55143 | CDCA8 | P36T-E | Human | Esophagus | ESCC | 7.72e-03 | 1.73e-01 | 0.1187 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:014001414 | Esophagus | ESCC | mitotic nuclear division | 218/8552 | 287/18723 | 6.17e-26 | 1.78e-23 | 218 |
| GO:005165617 | Esophagus | ESCC | establishment of organelle localization | 273/8552 | 390/18723 | 9.13e-23 | 1.81e-20 | 273 |
| GO:000007011 | Esophagus | ESCC | mitotic sister chromatid segregation | 138/8552 | 168/18723 | 1.37e-22 | 2.63e-20 | 138 |
| GO:00008194 | Esophagus | ESCC | sister chromatid segregation | 157/8552 | 202/18723 | 8.41e-21 | 1.33e-18 | 157 |
| GO:000705911 | Esophagus | ESCC | chromosome segregation | 238/8552 | 346/18723 | 1.72e-18 | 1.82e-16 | 238 |
| GO:005131011 | Esophagus | ESCC | metaphase plate congression | 58/8552 | 65/18723 | 1.81e-13 | 8.63e-12 | 58 |
| GO:000708011 | Esophagus | ESCC | mitotic metaphase plate congression | 47/8552 | 50/18723 | 3.15e-13 | 1.47e-11 | 47 |
| GO:00482853 | Esophagus | ESCC | organelle fission | 301/8552 | 488/18723 | 4.64e-13 | 2.12e-11 | 301 |
| GO:00988133 | Esophagus | ESCC | nuclear chromosome segregation | 187/8552 | 281/18723 | 1.00e-12 | 4.36e-11 | 187 |
| GO:005130311 | Esophagus | ESCC | establishment of chromosome localization | 67/8552 | 80/18723 | 1.92e-12 | 8.09e-11 | 67 |
| GO:005000011 | Esophagus | ESCC | chromosome localization | 68/8552 | 82/18723 | 3.37e-12 | 1.32e-10 | 68 |
| GO:00002802 | Esophagus | ESCC | nuclear division | 270/8552 | 439/18723 | 1.17e-11 | 4.24e-10 | 270 |
| GO:014001411 | Liver | HCC | mitotic nuclear division | 174/7958 | 287/18723 | 3.74e-10 | 1.23e-08 | 174 |
| GO:005165621 | Liver | HCC | establishment of organelle localization | 226/7958 | 390/18723 | 4.15e-10 | 1.34e-08 | 226 |
| GO:0000070 | Liver | HCC | mitotic sister chromatid segregation | 110/7958 | 168/18723 | 1.42e-09 | 4.25e-08 | 110 |
| GO:00008191 | Liver | HCC | sister chromatid segregation | 128/7958 | 202/18723 | 1.59e-09 | 4.73e-08 | 128 |
| GO:0007059 | Liver | HCC | chromosome segregation | 197/7958 | 346/18723 | 3.57e-08 | 7.87e-07 | 197 |
| GO:0098813 | Liver | HCC | nuclear chromosome segregation | 157/7958 | 281/18723 | 3.82e-06 | 4.95e-05 | 157 |
| GO:0048285 | Liver | HCC | organelle fission | 254/7958 | 488/18723 | 1.07e-05 | 1.23e-04 | 254 |
| GO:0007080 | Liver | HCC | mitotic metaphase plate congression | 36/7958 | 50/18723 | 2.28e-05 | 2.41e-04 | 36 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CDCA8 | SNV | Missense_Mutation | novel | c.79N>C | p.Asp27His | p.D27H | Q53HL2 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-B6-A0I2-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CDCA8 | SNV | Missense_Mutation | novel | c.676N>C | p.Glu226Gln | p.E226Q | Q53HL2 | protein_coding | deleterious(0.01) | possibly_damaging(0.874) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CDCA8 | SNV | Missense_Mutation | c.709N>A | p.Glu237Lys | p.E237K | Q53HL2 | protein_coding | tolerated(0.08) | benign(0.005) | TCGA-EW-A1OY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| CDCA8 | SNV | Missense_Mutation | rs761391083 | c.527G>A | p.Arg176Gln | p.R176Q | Q53HL2 | protein_coding | deleterious(0.01) | probably_damaging(0.992) | TCGA-AA-3710-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CDCA8 | SNV | Missense_Mutation | rs187658080 | c.719G>A | p.Arg240Gln | p.R240Q | Q53HL2 | protein_coding | tolerated(0.08) | probably_damaging(0.998) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| CDCA8 | SNV | Missense_Mutation | c.398A>G | p.Glu133Gly | p.E133G | Q53HL2 | protein_coding | tolerated(0.32) | benign(0.003) | TCGA-AD-6964-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folfox | PD | |
| CDCA8 | SNV | Missense_Mutation | c.64G>A | p.Ala22Thr | p.A22T | Q53HL2 | protein_coding | tolerated(0.21) | benign(0.005) | TCGA-AM-5821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CDCA8 | SNV | Missense_Mutation | c.85N>T | p.Asp29Tyr | p.D29Y | Q53HL2 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-G4-6588-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| CDCA8 | SNV | Missense_Mutation | novel | c.559N>T | p.Gly187Cys | p.G187C | Q53HL2 | protein_coding | tolerated(0.19) | probably_damaging(0.944) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CDCA8 | SNV | Missense_Mutation | novel | c.689N>T | p.Thr230Ile | p.T230I | Q53HL2 | protein_coding | deleterious(0) | possibly_damaging(0.609) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |